| Basics |
Esperion Therapeutics, Inc.
Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.
|
| IPO Date: |
June 26, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$884.27M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.74 | 3.26%
|
| Avg Daily Range (30 D): |
$0.11 | 3.63%
|
| Avg Daily Range (90 D): |
$0.09 | 3.65%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.63M |
| Avg Daily Volume (30 D): |
6.17M |
| Avg Daily Volume (90 D): |
6.31M |
| Trade Size |
| Avg Trade Size (Sh.): |
212 |
| Avg Trade Size (Sh.) (30 D): |
322 |
| Avg Trade Size (Sh.) (90 D): |
400 |
| Institutional Trades |
| Total Inst.Trades: |
3,063 |
| Avg Inst. Trade: |
$1.79M |
| Avg Inst. Trade (30 D): |
$.96M |
| Avg Inst. Trade (90 D): |
$.95M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.23M |
| Avg Closing Trade (30 D): |
$1.04M |
| Avg Closing Trade (90 D): |
$1.06M |
| Avg Closing Volume: |
115.63K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.54
|
$-.16
|
|
|
Diluted EPS
|
$-.54
|
$-.16
|
|
|
Revenue
|
$ 303.8M
|
$ 87.31M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -105.83M
|
$ -31.33M
|
$ -12.73M
|
|
Operating Income / Loss
|
$ -29.38M
|
$ -9.96M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ .04M
|
$
|
$
|
|
PE Ratio
|
|
|
|
|
|
|
